Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular disease prevalence in adults with type 2 diabetes in Japan: results from the Japanese centers in the CAPTURE study

  • Original Article
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

Introduction

CAPTURE was a cross-sectional, non-interventional study (NCT03786406, NCT03811288) investigating the prevalence and characteristics of cardiovascular disease (CVD) in adults with type 2 diabetes (T2D) across 13 countries worldwide. Here we present the findings for Japan.

Materials and methods

Data were collected from adults aged ≥ 20 years (aged ≥ 18 years in countries outside Japan) with T2D who were managed in clinics or hospitals in 2019. Standardized methodology was used for all countries. The prevalence of CVD and its subtypes was estimated, weighted by care setting (clinics versus hospitals).

Results

Among participants from Japan (total: 800; clinics: 440; hospitals: 360), mean (standard deviation) age was 65.6 (11.2) years and glycated hemoglobin 7.2% (0.9). Sixty-seven percent of participants were male, 57.8% had diabetes duration > 10 years, 49.8% had body mass index ≥ 25 kg/m2 and 63.1% had hypertension. The weighted prevalences (95% confidence interval [CI]) of CVD and atherosclerotic CVD were 37.3% (34.2;40.3) and 33.5% (30.6;36.4), respectively. The prevalence (95% CI) of the most common subtypes of CVD was: carotid artery disease 20.5% (18.2;22.8), coronary heart disease 11.9% (9.7;14.1) and cerebrovascular disease 10.4% (8.3;12.5).

Conclusions

These contemporary data from the CAPTURE study on CVD prevalence in adults with T2D in Japan show that approximately one in three adults with T2D had established CVD, which is comparable to the prevalence in the global study cohort.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The patient level analysis data sets for the research presented in this publication are available from the corresponding author on reasonable request.

References

  1. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129–40.

    Article  CAS  PubMed  Google Scholar 

  2. Ramachandran A, Snehalatha C, Shetty AS, Nanditha A. Trends in prevalence of diabetes in Asian countries. World J Diabetes. 2012;3:110–7.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Mukai N, Doi Y, Ninomiya T, Hirakawa Y, Nagata M, Yoshida D, et al. Trends in the prevalence of type 2 diabetes and prediabetes in community-dwelling Japanese subjects: the Hisayama study. J Diabetes Investig. 2014;5:162–9.

    Article  PubMed  Google Scholar 

  4. International Diabetes Federation: IDF Diabetes Atlas, 9th edn. Brussels, Belgium: International Diabetes Federation; 2019.

  5. World Health Organization (WHO). Diabetes Factsheet. 2021. https://www.who.int/news-room/fact-sheets/detail/diabetes. Accessed Mar 2022.

  6. Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10:14790.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Yang JJ, Yu D, Wen W, Saito E, Rahman S, Shu X-O, et al. Association of diabetes with all-cause and cause-specific mortality in Asia: a pooled analysis of more than 1 million participants. JAMA Netw Open. 2019;2: e192696.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Gerstein HC. Diabetes: dysglycaemia as a cause of cardiovascular outcomes. Nat Rev Endocrinol. 2015;11:508–10.

    Article  CAS  PubMed  Google Scholar 

  9. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Angelantonio D, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.

    Article  CAS  PubMed  Google Scholar 

  10. Nakamura J, Kamiya H, Haneda M, Inagaki N, Tanizawa Y, Araki E, et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: Report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig. 2017;8:397–410.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Tanaka S, Tanaka S, Iimuro S, Yamashita H, Katayama S, Ohashi Y, Akanuma Y, Yamada N, Sone H, Japan Diabetes Complications Study Group. Cohort profile: The Japan diabetes complications study: a long-term follow-up of a randomised lifestyle intervention study of type 2 diabetes. Int J Epidemiol. 2014;43:1054–62.

    Article  PubMed  Google Scholar 

  12. Sone H, Tanaka S, Iimuro S, Tanaka S, Oida K, Yamasaki Y, et al. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia. 2010;53:419–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ohsugi M, Eiki JI, Iglay K, Tetsuka J, Tokita S, Ueki K. Comorbidities and complications in Japanese patients with type 2 diabetes mellitus: retrospective analyses of J-DREAMS, an advanced electronic medical records database. Diabetes Res Clin Pract. 2021;178: 108845.

    Article  PubMed  Google Scholar 

  14. American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S111–S34.

  15. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.

    Article  PubMed  Google Scholar 

  16. Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi JL Jr, Kalyani RR, et al. Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76:1117–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Araki E, Tanaka A, Inagaki N, Ito H, Ueki K, Murohara T, et al. Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. Diabetol Int. 2021;12:1–51.

    Article  PubMed  Google Scholar 

  18. Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, Darmon P, Davis TME, et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021;20:154.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.

    Article  Google Scholar 

  20. International Society for Pharmacoepidemiology (ISPE). Guidelines for Good Pharmacoepidemiology Practices (GPP). https://www.pharmacoepi.org/resources/policies/guidelines‐08027/. Accessed Feb 2020.

  21. Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671–9.

    Article  CAS  PubMed  Google Scholar 

  22. Tanaka S, Tanaka S, Iimuro S, Yamashita H, Katayama S, Akanuma Y, et al. Predicting macro- and microvascular complications in type 2 diabetes: the Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care. 2013;36:1193–9.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306.

    Article  CAS  PubMed  Google Scholar 

  24. Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, et al. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program. J Am Soc Nephrol. 2019;30:2229–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Fujihara K, Sone H. Cardiovascular disease in Japanese patients with type 2 diabetes mellitus. Ann Vasc Dis. 2018;11:2–14.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Ishikawa S, Kayaba K, Gotoh T, Nago N, Nakamura Y, Tsutsumi A, et al. Incidence of total stroke, stroke subtypes, and myocardial infarction in the Japanese population: the JMS Cohort Study. J Epidemiol. 2008;18:144–50.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb. 2018;25:846–984.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Iso H. A Japanese health success story: trends in cardiovascular diseases, their risk factors, and the contribution of public health and personalized approaches. EPMA J. 2011;2:49–57.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Yokoyama H, Araki SI, Kawai K, Yamazaki K, Tomonaga O, Shirabe SI, et al. Declining trends of diabetic nephropathy, retinopathy and neuropathy with improving diabetes care indicators in Japanese patients with type 2 and type 1 diabetes (JDDM 46). BMJ Open Diabetes Res Care. 2018;6: e000521.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Shai I, Jiang R, Manson JE, Stampfer MJ, Willett WC, Colditz GA, et al. Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes Care. 2006;29:1585–90.

    Article  PubMed  Google Scholar 

  32. The D-DSG, on behalf of the European Diabetes Epidemiology G, and the International Diabetes Epidemiology G. Age, body mass index and Type 2 diabetes—associations modified by ethnicity. Diabetologia. 2003;46:1063–70.

  33. Park Y-W, Allison DB, Heymsfield SB, Gallagher D. Larger amounts of visceral adipose tissue in Asian Americans. Obes Res. 2001;9:381–7.

    Article  CAS  PubMed  Google Scholar 

  34. Tanaka S, Horimai C, Katsukawa F. Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis. Acta Diabetol. 2003;40(Suppl 1):S302–4.

    Article  PubMed  Google Scholar 

  35. Yabe D, Seino Y, Fukushima M, Seino S. Beta cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15:602.

    Article  PubMed  Google Scholar 

  36. Fujimoto WY, Abbate SL, Kahn SE, Hokanson JE, Brunzell JD. The visceral adiposity syndrome in Japanese-American men. Obes Res. 1994;2:364–71.

    Article  CAS  PubMed  Google Scholar 

  37. Fukuda T, Bouchi R, Takeuchi T, Nakano Y, Murakami M, Minami I, et al. Ratio of visceral-to-subcutaneous fat area predicts cardiovascular events in patients with type 2 diabetes. J Diabetes Investig. 2018;9:396–402.

    Article  CAS  PubMed  Google Scholar 

  38. Tsugane S. Why has Japan become the world’s most long-lived country: insights from a food and nutrition perspective. Eur J Clin Nutr. 2021;75:921–8.

    Article  PubMed  Google Scholar 

  39. Araki E, Tanaka A, Inagaki N, Ito H, Ueki K, Murohara T, et al. Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and pre-diabetes: a consensus statement joined from the Japanese circulation society and The Japan Diabetes Society. Circ J. 2020;85:82–125.

    Article  PubMed  Google Scholar 

  40. Hata J, Ninomiya T, Hirakawa Y, Nagata M, Mukai N, Gotoh S, et al. Secular trends in cardiovascular disease and its risk factors in Japanese: half-century data from the Hisayama Study (1961–2009). Circulation. 2013;128:1198–205.

    Article  PubMed  Google Scholar 

  41. Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6:691–704.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Novo Nordisk A/S funded medical writing support, provided by Gillian Groeger, PhD, and Arezou Hossein, MPharm, and editorial assistance, provided by Izabel James, MBBS, all of Ashfield MedComms, an Ashfield Health company, part of UDG Healthcare.

Funding

Novo Nordisk A/S.

Author information

Authors and Affiliations

  1. Seino Internal Medicine Clinic, 6-192-2 Kaisei, Koriyama, Fukushima, 963-8851, Japan

    Hiroaki Seino

  2. The Institute of Medical Science, Asahi Life Foundation, Tokyo, Japan

    Yukiko Onishi

  3. Novo Nordisk Pharma Ltd, Tokyo, Japan

    Kosei Eguchi, Keiji Nishijima & Toshihiro Sato

  4. HEC Science Clinic, Yokohama, Japan

    Shinichiro Shirabe

Authors
  1. Hiroaki Seino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yukiko Onishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kosei Eguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keiji Nishijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toshihiro Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shinichiro Shirabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroaki Seino.

Ethics declarations

Conflict of interest

HS: research funding from Astellas Pharma Inc., Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, Novo Nordisk Pharma, Sanofi, Mitsubishi Tanabe Pharma Co., Novartis Pharma K.K., Shionogi Pharma Co., Ltd, Boehringer Ingelheim, AstraZeneca K.K. and MSD; honoraria from Shionogi Pharma Co., Mitsubishi Tanabe Pharma Co., Astellas Pharma Inc., Novartis Pharma K.K., Eli Lilly, Ono Pharmaceutical Co., MSD and Sanofi; YO: Honoraria/lecture fees from Ono Pharmaceutical, Novo Nordisk Pharm Ltd and Sumitomo Pharma; research funding from Eli Lilly, Novo Nordisk Pharm Ltd and Save Medical; KN: Novo Nordisk employee and shareholder; KE and TS: Novo Nordisk employees; SS: Lecture fees from Sumitomo Pharma, Eli Lilly and Novo Nordisk.

Ethical statements

Approval of the research protocol

The protocol was approved by the IEC or other appropriate body and provided by each investigator prior to undertaking any study-related activities.

Registration number and approval date of registry of the trials: NCT03786406, 26 December 2018, and NCT03811288, 22 January 2019.

Human research

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and/or with the Helsinki Declaration of 1964 and later versions. Informed consent was provided by each patient prior to undertaking any study-related activities (during the first and only study visit).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 111 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seino, H., Onishi, Y., Eguchi, K. et al. Cardiovascular disease prevalence in adults with type 2 diabetes in Japan: results from the Japanese centers in the CAPTURE study. Diabetol Int 14, 172–182 (2023). https://doi.org/10.1007/s13340-022-00612-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-022-00612-y

Keywords

Search

Navigation